Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Repeated 0.5-Gy gamma irradiation attenuates autoimmune disease in MRL-lpr/lpr mice with suppression of CD3+CD4-CD8-B220+ T-cell proliferation and with up-regulation of CD4+CD25+Foxp3+ regulatory T cells.
Tago F, Tsukimoto M, Nakatsukasa H, Kojima S. Tago F, et al. Radiat Res. 2008 Jan;169(1):59-66. doi: 10.1667/RR1013.1. Radiat Res. 2008. PMID: 18159952
Tago, F., Tsukimoto, M., Nakatsukasa, H. and Kojima. S. Repeated 0.5 Gy Gamma Irradiation Attenuates Autoimmune Disease in MRL-lpr/lpr Mice with Suppression of CD3(+)CD4(-)CD8(-)B220(+) T-Cell Proliferation and with Up-regulation of CD4(+)CD25(+)Foxp3(+) Regulatory …
Tago, F., Tsukimoto, M., Nakatsukasa, H. and Kojima. S. Repeated 0.5 Gy Gamma Irradiation Attenuates Autoimmune Disease in MRL …
Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in Patients With Active Rheumatoid Arthritis With Inadequate Response to Methotrexate: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Study.
Tanaka Y, Takeuchi T, Yamanaka H, Nanki T, Umehara H, Yasuda N, Tago F, Kitahara Y, Kawakubo M, Torii K, Hojo S, Kawano T, Imai T. Tanaka Y, et al. Among authors: tago f. Arthritis Rheumatol. 2021 Apr;73(4):587-595. doi: 10.1002/art.41555. Epub 2021 Feb 18. Arthritis Rheumatol. 2021. PMID: 33038062 Free PMC article. Clinical Trial.
Emerging Role of Fractalkine in the Treatment of Rheumatic Diseases.
Tanaka Y, Hoshino-Negishi K, Kuboi Y, Tago F, Yasuda N, Imai T. Tanaka Y, et al. Among authors: tago f. Immunotargets Ther. 2020 Nov 4;9:241-253. doi: 10.2147/ITT.S277991. eCollection 2020. Immunotargets Ther. 2020. PMID: 33178636 Free PMC article. Review.
First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742, a Dual Antagonist of Toll-like Receptors 7 and 8, in Healthy Volunteers.
Yamakawa N, Tago F, Nakai K, Kitahara Y, Ikari S, Hojo S, Hall N, Aluri J, Hussein Z, Gevorkyan H, Maruyama T, Ishizaka S, Yagi T. Yamakawa N, et al. Among authors: tago f. Clin Pharmacol Drug Dev. 2023 Apr;12(4):363-375. doi: 10.1002/cpdd.1176. Epub 2022 Oct 11. Clin Pharmacol Drug Dev. 2023. PMID: 36219471 Clinical Trial.
A phase 2 study of E6011, an anti-Fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugs.
Tanaka Y, Takeuchi T, Yamanaka H, Nanki T, Umehara H, Yasuda N, Tago F, Kitahara Y, Kawakubo M, Torii K, Hojo S, Kawano T, Imai T. Tanaka Y, et al. Among authors: tago f. Mod Rheumatol. 2021 Jul;31(4):783-789. doi: 10.1080/14397595.2020.1868675. Epub 2021 Feb 2. Mod Rheumatol. 2021. PMID: 33427546 Clinical Trial.
14 results